-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau reports 100% local disease control in pooled Alpha DaRT pancreatic trials

PUBT·05/04/2026 13:01:28
Listen to the news
Alpha Tau reports 100% local disease control in pooled Alpha DaRT pancreatic trials
  • Alpha Tau Medical reported updated pooled results from two first-in-human pancreatic cancer trials that were presented at Digestive Disease Week 2026.
  • Treated patients achieved local disease control, supporting an efficacy signal in a setting with limited treatment options.
  • Safety profile was described as favorable, with few device-related adverse events that largely resolved quickly.
  • Procedure uses outpatient endoscopic ultrasound delivery, positioning Alpha DaRT for integration into routine GI endoscopy workflows.
  • Data were framed as supporting continued development, including advancement of its ongoing U.S. multicenter pancreatic cancer IMPACT trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-051176), on May 04, 2026, and is solely responsible for the information contained therein.